Abstract
Introduction:
Ophthalmic involvement occurs in up to 40% of patients with granulomatosis with polyangiitis (GPA), usually confined to the anterior segment. Herein, we describe patients presenting with optic neuropathy as an early manifestation of GPA, without other signs of ocular or adnexa involvement.
Methods:
We report a case of isolated optic neuropathy without other ocular or adnexal involvement and examine the reported clinical features of 17 additional patients through a literature review. We analyzed clinical characteristics and neuro-ophthalmological findings and discuss the clinical implications for the early detection of GPA-associated optic neuropathy.
Results:
Among the 17 patients, 10 had optic neuropathy confined to one eye, three exhibited simultaneous bilateral optic neuropathies at initial presentation, and four had unilateral involvement initially; however, the fellow eye was subsequently affected during follow-up. Nine patients had optic neuropathy as the first clinical presentation and no prior diagnosis of GPA (9/17, 53%). Among the 21 eyes (15 patients, excluding two without descriptions), disc edema was observed in five eyes (24%). Visual impairment was often profound; the measurements of 23 affected eyes at the initial presentation showed that the patient’s acuity was to count fingers or worse (14/23, 61%). The final visual outcome was often poor, with significant visual recovery in only eight eyes (8/23, 35%). Other constitutional symptoms or systemic involvements were found in most patients (15/16, 94%), mostly affecting the lung (n = 10), sinus (n = 9), and pachymeninges (n = 8). Furthermore, 88% of the patients (15/17) showed positive results on antineutrophil cytoplastic antibody. Elevated CRP (n = 6) or ESR (n = 5) was found in 56% of cases.
Discussion:
Our case and literature review indicates that optic neuropathy can present in the context of systemic inflammation of GPA, without any other signs of ocular or orbital involvement. Catching other clinical, imaging, and laboratory signs of systemic inflammation is important in cases of GPA-associated optic neuropathy with atypical presentations.
1 Introduction
Granulomatosis with polyangiitis (GPA), previously referred to as Wegener’s granulomatosis, is an autoimmune vasculitis affecting small- and medium-sized blood vessels (1). This condition may involve various organs, including the sinuses, nose, throat, lungs, and kidneys, typically presenting as rhinitis, chronic otitis media, pneumonia, or glomerulonephritis. Ophthalmic involvement is observed in up to 40% of patients (2), primarily affecting the anterior segment (2–5). Although rare, the optic nerve can also be affected, mostly due to granulomatous lesions or direct spread of inflammation from the sinuses (2).
We recently encountered an unusual case of acute unilateral optic neuropathy as the first presentation of GPA. The diagnosis posed a challenge, as imaging revealed no granulomatous inflammation, and there was no evidence of ocular or ocular adnexal involvement. This implies that optic neuropathy can result from in situ pathology in the optic nerve, aside from direct compression from inflammation in GPA, as is conventionally known. Defining these patients is important because treatment considerations are different for GPA optic neuropathy versus demyelinating optic neuritis. Thus, we report the details of this case and provide a systematic review of the literature on optic neuropathy without any other signs of ocular or ocular adnexal involvement as a rare presentation of GPA.
2 Methods
Written informed consent was obtained from the patient for the publication of any potentially identifiable images or data included in this article.
2.1 Case report
2.1.1 History and examination
An 80-year-old female with hypertension and diabetes mellitus presented with an acute decrease in visual acuity in the right eye for 2 days. The patient experienced an unexplained fever and a weight loss of 6 kg in the month prior to presentation. The patient did not report diplopia, ocular pain, headache, or dizziness.
The patient underwent a comprehensive ophthalmic examination with the following pertinent findings. The eyes were orthophoric with intact versions and ductions. Her visual acuity measurements showed light perception in the right eye and 20/40 in the left. Both pupils were round, isocoric, and reactive to light and accommodative stimuli. A relative afferent pupillary defect was observed in the right eye. Other neurologic examinations, including palpation of the preauricular and forehead arteries, were normal. Fundus examination revealed a pallid disc edema in the right eye.
Standard automated perimetry using the Humphrey Visual Field Analyzer (program 24-2 full threshold, white stimulus; Carl Zeiss Meditec, Dublin, United States) showed global depression in the right eye and normal findings in the left eye. The optical coherence tomography (OCT, Cirrus; Carl Zeiss Meditec, Dublin, United States) showed marked thickening of retinal nerve fiber layer in right eye consistent with disc edema (Figure 1A). Fluorescein angiography was not performed because the marginal glomerular filtration rate was 26.6 mL/min/1.73 m2. No responses were obtained during right-eye stimulation of visually evoked potentials. The visually evoked potential showed normal response in the left eye.
Figure 1
2.1.2 Ancillary testing
Although chest X-ray was unrevealing, chest CT revealed multiple ill-defined nodules and ground-glass opacity less than 1 cm in the right middle lobe. Urine analysis showed proteinuria of 1+. A gadolinium enhancement was found around the right optic nerve sheath on MRI (Figure 1B). Multifocal enhancements were documented in the bilateral temporalis, masseter, and pterygoid muscles, aside from maxillary sinusitis and mastoiditis. Whole-body positron emission tomography showed increased glucose uptake in the popliteal and femoral arteries (Figure 1C). The serum was positive for cytoplasmic antineurtrophil cytoplasmic antibody (cANCA) and negative for perinuclear ANCA (pANCA). The serum titer of anti-myeloperoxidase antineutrophil cytoplasmic antibody increased to 105.0 IU/mL (MPO-ANCA, normal range = 0–2 IU/mL), whereas that of anti-proteinase 3 antineutrophil cytoplasmic antibodies (PR3-ANCA) was normal using an enzyme-linked immunosorbent assay. The erythrocyte sedimentation rate (ESR, 92 mm/h) and C-reactive protein level (CRP, 145.0 mg/L) were elevated. The serum was negative for anti-aquaporin-4, anti-myelin oligodendrocyte glycoprotein, and paraneoplastic antibodies. CSF analysis revealed no leukocytosis or albuminocytologic dissociation but showed positive results for the oligoclonal band. A kidney biopsy documented pauci-immune crescentic glomerulonephritis compatible with the diagnosis of GPA (Figure 2).
Figure 2
2.1.3 Diagnosis
The patient was diagnosed with optic neuropathy associated with GPA. The patient scored 9 points on 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology (ACR/EULAR) classification criteria (5 points for cANCA, 2 points for pulmonary nodule, 1 point for maxillary sinusitis and mastoiditis on MRI, and 1 point for pauci-immune glomerulonephritis on biopsy) (6).
2.1.4 Treatment and clinical course
The patient received intravenous methylprednisolone (1 g/day) for five consecutive days. Intravenous rituximab (1,000 mg) was administered for immunomodulation. Three months later, optic disc pallor was observed in the right eye. Visual acuity measurements showed light perception in the right eye and at 20/25 in the left. Recurrence was not observed during the 2-year follow-up, and immunomodulation was maintained with intravenous rituximab.
2.2 Literature search
We performed a literature search using PubMed (up to August 2024). The search keywords included optic neuropathy, optic neuritis, Wegener’s granulomatosis, and granulomatosis with polyangiitis. We included all patients described in the systematic reviews, clinical studies, and case reports published in English. The references cited in the retrieved articles were also reviewed. The diagnosis of optic neuropathy/neuritis as an isolated manifestation was based on (1) documented optic nerve involvement, (2) documentation and quantification of nerve damage using neuro-ophthalmologic examination and evaluation, and (3) the absence of any other ocular or ocular adnexa abnormalities.
We analyzed the clinical characteristics of the patients: the bilaterality of optic nerve involvement, best-corrected visual acuities recorded at initial presentation and the final visit, and results of neuro-ophthalmologic evaluation and serologic, cerebrospinal fluid (CSF), and magnetic resonance imaging (MRI) findings.
3 Results
A comprehensive literature review identified 13 studies describing 17 patients who met the search criteria (6 female, age range: 32–87 years, median age: 64 years, mean age ± standard deviation = 64 ± 14; Figure 3 and Table 1). Fourteen patients were found to have isolated optic neuropathy associated with GPA. Three patients initially presented with optic neuropathy in isolation but subsequently developed strabismus during follow-up due to abducens (n = 2), oculomotor (n = 2), or trochlear nerve palsy (n = 1; Table 1).
Figure 3
Table 1
| Author, year | Sex/age | Timing of optic nerve involvement | Optic nerve involvement | Fundus findingsa | Visual acuitya | Other organ involvement or vegetative symptom | Serology | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Initial | Final | MPO-ANCA (IU/mL) or pANCA | PR3-ANCA (IU/mL) or cANCA | CRP (mg/L) | ESR (mm/h) | ||||||
| Our study | F/80 | Initial | OD | Pallid disc edema | LP | LP | Kidney, large vessel, fever, weight loss | MPO-ANCA (105.0) | cANCA (1:80) | 145 | 92 |
| Belden et al., 1993 (27) | F/55 | During the disease process | OU, sequential (OS → OD) | Normal | FC, HM | FC, FC | Lung, sinus, pachymeninges, skin/connective tissue (nasal septum), colon | Unknown | cANCA (52) | Unknown | 72 |
| Duran et al., 2004 (9) | M/67 | Initial | OD | Disc edema | Unknown | Normal | Kidney, joint | MPO-ANCA (907) | — | Unknown | 75 |
| Monteiro et al., 2005 (8) | M/32 | Initial | OU, sequential (OD → OS) | Normal, disc edema | FC, NLP | 20/20, 20/30 | Lung, sinus, skin/connective tissue (nasal septum), hearing loss, facial nerve | — | cANCA (+) | Unknown | Unknown |
| Blaise et al., 2007 (28) | F/69 | Initial | OU, sequential (OD → OS) | Normal | NLP, LP | LP, LP | Weight loss | pANCA (+) | cANCA (+) | Normal | Normal |
| Blaise et al., 2007 (28) | F/58 | During the disease process | OS | Unknown | LP | LP | Lung, weight loss | — | — | Unknown | Unknown |
| Purvin and Kawasaki, 2009 (16) | M/53 | Initial | OS | Disc hyperemia | 20/20 | 20/20 | Lung | pANCA normal | cANCA (12) | Normal | Normal |
| Huchzermeyer et al., 2013 (29)b | F/56 | During the disease process | OD | Normal | 20/100 | 20/25 | Skin/connective tissue (nasal septum, saddle nose) | Unknown | PR3-ANCA +, cANCA (60) | Unknown | Unknown |
| Nagaoka et al., 2012 (30) | M/71 | Initial | OU | Unknown | NLP, 20/40 | Unknown | Lung, pachymeninges | Unknown | PR3-ANCA | Unknown | Unknown |
| Takazawa et al., 2014 (31) | M/74 | Initial | OU, sequential (OD → OS) | Normal | NLP, 20/100 | NLP, 20/20 | Lung, pachymeninges, kidney, skin/connective tissue (nasal cavity, throat) | Unknown | PR3-ANCA | 8.9 | Unknown |
| Takazawa et al., 2014 (31) | M/72 | Initial | OU | Normal | NLP, 20/40 | Complete resolution | Lung, sinus, pachymeninges, chronic otitis media | Unknown | PR3-ANCA | 8.9 | >100 |
| Nakajima et al., 2016 (32) | F/87 | Initial | OS | Normal | LP | Improvement | Pachymeninges | MPO-ANCA (5.1) | PR3-ANCA (7.1) | 9.25 | Unknown |
| Clément et al., 2019 (20)b | M/39 | During the disease process | Unilateral (eye not specified) | Optic atrophy | 20/200 | NLP | Lung, sinus, fever, weight loss, joint | — | PR3-ANCA | 188 | Unknown |
| Clément et al., 2019 (20)b | F/69 | During the disease process | Unilateral (eye not specified) | Normal | FC | NLP | Sinus, pachymeninges, joint, pericardium | MPO-ANCA | — | Normal | Unknown |
| Clément et al., 2019 (20) | M/64 | During the disease process | Unilateral (eye not specified) | Normal | 20/200 | 20/32 | Sinus, pachymeninges, fever, joint, peripheral nerve | MPO-ANCA | — | Normal | Unknown |
| Suga et al., 2019 (33) | M/61 | During the disease process | OU | Disc edema | 20/20, 20/1,000 | 20/20, 20/2,000 | Lung, sinus, fever, weight loss | — | — | 8.24 | Unknown |
| Mitsuhashi et al., 2020 (34) | M/60 | During the disease process | OS | Disc edema | 20/2,000 | 20/16 | Sinus, fever, vestibulocochlear nerve | MPO-ANCA (6.2) | — | Normal | Unknown |
| Sato-Akushichi et al., 2021 (35) | M/79 | Initial | OS | Normal | LP | 20/25 | Lung, sinus, pachymeninges, kidney | MPO-ANCA (19.5) | — | Normal | 31 |
Literature review of the cases presenting with optic neuropathy without other ocular or ocular adnexal involvement in granulomatosis with polyangiitis.
ANCA, anti-neutrophil cytoplasmic antibody; cANCA, cytoplasmic ANCA; CRP, C-reactive protein; F, female; ESR, erythrocyte sedimentation rate; FC, finger count; HM, hand motion; L, light perception; M, male; NLP, no light perception; OD, right eye; OS, left eye; OU, both eyes; pANCA, perinuclear ANCA.
OD, OS in case of bilateral involvement.
These patients initially presented with optic neuropathy in isolation and later developed strabismus during the disease course.
Nine patients presented with optic neuropathy as the first clinical presentation, with no prior diagnosis of GPA (9/17, 53%). Systemic involvement was observed in most cases (15/16, 94%), affecting the lungs (n = 10), sinuses (n = 9), pachymeninges (n = 8), joints (n = 4), kidneys (n = 3), skin/connective tissue (n = 4), inner/middle ear (n = 2), pericardium (n = 1), colon (n = 1), and cranial (n = 2) or peripheral nerves (n = 1). Six patients (35%) had preceding constitutional symptoms, such as fever (n = 4) or weight loss (n = 4).
Among the 17 patients, 10 had optic neuropathy confined to either eye, three exhibited simultaneous bilateral optic neuropathy at the initial presentation, and four had unilateral involvement initially; however, the fellow eye was subsequently affected during follow-up, with a time interval of 2 months to 1 year. Among the 21 eyes (15 patients, excluding two lacking description), disc edema was observed in five eyes (24%). The initial visual acuity was usually poor; the measurements of 14 affected eyes showed the patient was only to count fingers (14/23, 61%). Visual field tests revealed various types of visual field defects, including central/cecocentral scotoma (n = 8), nasal step (n = 2), global depression (n = 1), peripheral constriction (n = 1), arcuate scotoma (n = 1), and temporal wedge (n = 1). The results of OCT was not reported in any of the patient.
Eighty-eight percent of patients (15/17) tested positive for ANCA, including MPO-ANCA (n = 7), PR3-ANCA (n = 6), cANCA (n = 5), or pANCA (n = 1). Elevated CRP (n = 6) or ESR (n = 5) was found in 56% (9/16) of patients. CSF analysis showed abnormal results in most cases (6/7, 86%), including albuminocytologic dissociation (n = 3), increased immunoglobulin G index (n = 3), pleocytosis (n = 2), and a positive oligoclonal band (n = 1). Chest X-ray and CT were abnormal in eight patients (8/11, 73%), showing pulmonary nodules (n = 7), infiltrates (n = 1), or peribronchial thickening (n = 1). Urinalysis was abnormal in three patients (3/5, 60%), including gross/microscopic hematuria (n = 3) or proteinuria (n = 1).
MRI was abnormal in most patients (13/16, 81%, excluding one without detailed description) and included enhancement of the optic nerve sheath (n = 10) and optic nerve (n = 3). Abnormal T2-weighted signal intensity was also found in the optic nerve in three patients (3/16, 19%). Notably, pachymeningeal enhancement (n = 9) or thickening (n = 4) was found in 10 patients (10/16, 63%).
The patients were treated with intravenous or oral steroids (n = 13), cyclophosphamide (n = 9), methotrexate (n = 2), rituximab (n = 5), mycophenolate mofetil (n = 1), azathioprine (n = 1), or plasmapheresis (n = 1). The final visual outcome was often poor, with significant visual recovery maintained in only eight eyes (8/23, 35%). Recurrence was observed in 10 patients (10/17, 59%) from one to four times, either in the affected eye (n = 9) or fellow eye (n = 4).
4 Discussion
Our findings can be summarized as follows: (1) we report a patient and further identified 17 patients whose optic nerves were affected by GPA in isolation, without other ocular or adnexal involvement. (2) Eighty-two percent of the patients showed unilateral optic neuropathy initially, although sequential involvement of the fellow eye or recurrence was frequently observed. (3) Although remarkable visual improvement was documented in one-third, the final visual outcome was often not favorable, with visual impairment (only to count fingers) in 41% of the eyes affected. (4) ANCA positivity and optic nerve sheath or pachymeningeal enhancement on MRI aided in the discrimination of optic neuropathy associated with GPA from demyelinating optic neuritis. (5) Identifying other constitutional symptoms and signs of systemic involvement helped guide the diagnosis of optic neuropathy associated with GPA.
4.1 Optic nerve involvement in GPA
Ocular involvement is observed in nearly 40% of patients with GPA and is mostly associated with anterior segment inflammation (3). Scleritis and episcleritis are the most common manifestations, whereas optic neuropathy is reported in only 3% of patients (3). Its pathogenesis is usually explained by extension of granulomatous inflammation from the sinus or orbit (2, 3, 5). Therefore, when it occurs, it is mostly accompanied by strabismus, and the optic nerve is damaged due to compression by granulomatous inflammation (2, 5). Notably, ocular involvement is the first presentation of GPA in 14% of patients (3). Our findings further suggest that optic neuropathy can be an isolated ocular manifestation, without accompanying signs of other ocular or ocular adnexal involvement (Table 1).
4.2 Mechanism of optic nerve damage in GPA
The mechanism of isolated optic nerve damage is unclear in GPA. Although granulomatous inflammation is not evident, the optic nerve can be damaged by compression due to pachymeningitis (7). Alternatively, it can be ascribed to inflammation spreading from the adjacent sinuses to involve the optic nerves in the orbital apex, optic canal, and intracranial segment (8). Ischemic optic neuropathy secondary to small vessel vascilitis has been proposed a possible mechanism based on temporal artery biopsy findings of leukocytic infiltration, fibrinoid necrosis and occlusion of the small periadvential vessel (vasa vasorum) in one of the reports (9). Focal vasculitis may cause ischemia and infarction of the optic nerve and retina to resulting in pallid disc edema, as in our patient (2, 9, 10). The findings of optic nerve sheath and orbital enhancement on the MRI brain and orbits in our patient supports ischemia from posterior ciliary arteries as a possible mechanism for optic neuropathy. The rapidity and severity of the visual loss, the disc appearance (i.e., pallid disc edema), marginal response to steroids, and poor visual outcome also support ischemic optic neuropathy in our patient.
Our case presentation and literature review of similar cases suggest an interplay between inflammation and ischemia resulting in optic nerve damage in GPA. Optic nerve sheath and orbital inflammation can result in ischemic infarction of optic nerve, which can worsen inflammation from the release of proinflammatory mediators from the ischemic endothelium and activation of intravascular leukocytes (11–14).
Optic perineuritis seen as enhancement of the optic nerve sheath on MRI orbits are seen in a variety of infectious and inflammatory conditions such as, syphilis, sarcoidosis, giant cell arteritis, and GPA (15, 16). Although distinct from demyelinating optic neuritis, it is also found in demyelinating optic neuritis (especially myelin oligodendrocyte glycoprotein optic neuritis) (17–19). Patients with perineuritis show a dramatic response to steroid treatment and are more likely to experience relapse during tapering the dose or following discontinuation of treatment than patients with optic neuritis (15). Collectively, our results suggest that, even when other ocular or ocular adnexal involvement is not evident, clinicians should be wary when encountering patients with acute visual impairment with an atypical age of onset in the context of other system involvement, ANCA positivity and MRI findings associated with optic nerve sheath enhancement.
4.3 Differentiation of optic neuropathy associated GPA and typical optic neuritis
In most patients, differentiation of optic neuropathy associated with GPA and “typical” optic neuritis can be challenging at initial presentation (20, 21). Compared with those with a demyelinating etiology, visual acuity can be profoundly impaired (only to count fingers) (20). Alternatively, visual acuity can be preserved in case of the inflammation being confined to the optic nerve sheath. Similar to demyelinating optic neuropathy, disc changes are occasionally observed in GPA optic neuropathy (up to 24%) as inflammation affects the variable portion along the length of the intra-orbital to intracranial portion of the optic nerve (i.e., retrobulbar; Table 1) (20).
In this context, differentiation is difficult when relying solely on neuro-ophthalmological manifestations. Patients with GPA optic neuropathy usually do not fall the typical age range for demyelinating optic neuritis (22–24). They may also have additional systemic symptoms such as fever, weight loss and generalized weakness. MRI orbits may show optic nerve sheath enhancement in addition to optic nerve enhancement. Serological inflammatory markers of positive ANCA (88%), elevated ESR/CRP (56%) may also aid in differentiation. Notably, inflammation involving other organs (up to 94%, mostly involving the lungs and sinuses) can serve as red flags for systemic vasculitic inflammation. Given that abnormal findings are anticipated in 60–83% of patients, chest X-ray/CT and urinalysis should be obtained in cases of optic neuropathy with atypical presentation.
4.4 Caveats and limitations of our study and suggestions for future research
Our study has some limitations. First, the number of patients with isolated optic neuropathy in the GPA group was relatively small. This may lead to failure to assume a pathomechanism and limit the generalization of our findings. However, defining these patients has clinical implications because the diagnosis is based mostly on systemic signs and symptoms, which can be easily overlooked by neuro-ophthalmologists (25, 26). Second, because neuro-ophthalmological studies were not systematically conducted, the neuro-ophthalmologic findings were rather heterogeneous. It remains to be clarified which neuro-ophthalmologic sign, if any, can provide distinctive differential features in GPA optic neuropathy as opposed to demyelinating ON. Third, the literature review included studies based on the authors’ own diagnoses. We could not decide whether each patient fulfils the ACR/EULAR classification, since many of the findings were omitted or not specified in prior works. Our study emphasizes the importance of early detection of GPA-associated optic neuropathy, which can have a grave prognosis. We hope this case report and literature review will serve as a springboard for future studies with refined, structured evaluation and diagnosis.
Our findings indicate that optic neuropathy can present in the context of systemic inflammation of GPA without any other signs of ocular or orbital involvement. Identifying clinical, imaging, and laboratory signs of systemic inflammation can be important in cases of visual impairment with atypical presentation.
Statements
Data availability statement
The datasets presented in this article are not readily available because of ethical and privacy restrictions. Requests to access the datasets should be directed to the corresponding author.
Ethics statement
The studies involving humans were approved by the Institutional Review Board of Korea University Anam Hospital (Approval Number: 2021AN0048). The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. Written informed consent was obtained from the patient for the publication of any potentially identifiable images or data included in this article.
Author contributions
YK: Data curation, Investigation, Methodology, Writing – original draft, Writing – review & editing. TW: Formal analysis, Methodology, Writing – review & editing. S-UL: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Software, Supervision, Validation, Writing – original draft, Writing – review & editing. EP: Supervision, Writing – review & editing. H-JS: Conceptualization, Supervision, Writing – review & editing. JS: Writing – original draft, Writing – review & editing, Data curation, Methodology. GK: Data curation, Funding acquisition, Writing – review & editing. J-SK: Supervision, Writing – review & editing.
Funding
The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This study was supported by the Basic Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Science and ICT (2022R1A4A1018869).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
J-SK serves as an Associate Editor of Frontiers in Neuro-otology and on the editorial boards of Frontiers in Neuro-ophthalmology, Journal of Neuro-ophthalmology, Journal of Vestibular Research, and Clinical and Translational Neuroscience, at the time of submission. This had no impact on the peer review process and the final decision.
Generative AI statement
The authors declare that no Gen AI was used in the creation of this manuscript.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1.
ComarmondCCacoubP. Granulomatosis with polyangiitis (Wegener): clinical aspects and treatment. Autoimmun Rev. (2014) 13:1121–5. doi: 10.1016/j.autrev.2014.08.017
2.
YangMKKimHWKangEHKimNChoungHKhwargSI. Ophthalmic manifestations and visual outcomes of granulomatosis with polyangiitis: a retrospective multicentre study in Korea. Eye. (2023) 37:1302–7. doi: 10.1038/s41433-022-02114-2
3.
AsínMAP-JCharlesPRothschildP-RTerrierBBrézinAMouthonLet al. Ocular involvement in granulomatosis with polyangiitis: a single-center cohort study on 63 patients. Autoimmun Rev. (2019) 18:493–500. doi: 10.1016/j.autrev.2019.03.001
4.
MeiLWangLYanH. Updates of ocular involvement in granulomatosis with polyangiitis. Graefes Arch Clin Exp Ophthalmol. (2023) 261:1515–23. doi: 10.1007/s00417-022-05918-w
5.
HaynesBFFishmanMLFauciASWolffSM. The ocular manifestations of Wegener’s granulomatosis: fifteen years experience and review of the literature. Am J Med. (1977) 63:131–41. doi: 10.1016/0002-9343(77)90125-5
6.
RobsonJCGraysonPCPonteCSuppiahRCravenAJudgeAet al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis. Arthritis Rheumatol. (2022) 74:393–9. doi: 10.1002/art.41986
7.
KupersmithMMartinVHellerGShahAMitnickH. Idiopathic hypertrophic pachymeningitis. Neurology. (2004) 62:686–94. doi: 10.1212/01.wnl.0000113748.53023.b7
8.
MonteiroMLRBorgesWISdo Val Ferreira RamosCLucatoLTLeiteCC. Bilateral optic neuritis in Wegener granulomatosis. J Neuroophthalmol. (2005) 25:25–8. doi: 10.1097/00041327-200503000-00007
9.
DuranEMerkelPSweetSSwanNBabikianV. ANCA-associated small vessel vasculitis presenting with ischemic optic neuropathy. Neurology. (2004) 62:152–3. doi: 10.1212/wnl.62.1.152
10.
ChirinosJATamarizLJLopesGDel CarpioFZhangXMilikowskiCet al. Large vessel involvement in ANCA-associated vasculitides: report of a case and review of the literature. Clin Rheumatol. (2004) 23:152–9. doi: 10.1007/s10067-003-0816-0
11.
LambertsenKLFinsenBClausenBH. Post-stroke inflammation—target or tool for therapy?Acta Neuropathol. (2019) 137:693–714. doi: 10.1007/s00401-018-1930-z
12.
VidaleSConsoliAArnaboldiMConsoliD. Postischemic inflammation in acute stroke. J Clin Neurol. (2017) 13:1–9. doi: 10.3988/jcn.2017.13.1.1
13.
ZhangCGuoYMillerNRBernsteinSL. Optic nerve infarction and post-ischemic inflammation in the rodent model of anterior ischemic optic neuropathy (rAION). Brain Res. (2009) 1264:67–75. doi: 10.1016/j.brainres.2008.12.075
14.
PannickeTIandievIUckermannOBiedermannBKutzeraFWiedemannPet al. A potassium channel-linked mechanism of glial cell swelling in the postischemic retina. Mol Cell Neurosci. (2004) 26:493–502. doi: 10.1016/j.mcn.2004.04.005
15.
PurvinVKawasakiAJacobsonDM. Optic perineuritis: clinical and radiographic features. Arch Ophthalmol. (2001) 119:1299–306. doi: 10.1001/archopht.119.9.1299
16.
PurvinVKawasakiA. Optic perineuritis secondary to Wegener’s granulomatosis. Clin Experiment Ophthalmol. (2009) 37:712–7. doi: 10.1111/j.1442-9071.2009.02122.x
17.
JangYKimS-MYunYILeeH-JKimS-JJungJHet al. Comparison between optic neuritis associated with antibody against myelin oligodendrocyte glycoprotein and presumed idiopathic optic perineuritis. Neurol Sci. (2020) 41:2755–60. doi: 10.1007/s10072-020-04371-z
18.
KimS-MWoodhallMRKimJ-SKimS-JParkKSVincentAet al. Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS. Neurol Neuroimmunol Neuroinflamm. (2015) 2:e163. doi: 10.1212/NXI.0000000000000163
19.
CaoYXuJYiZZhouL. A case of MOGAD complicated with cerebral vasculitis: case report and literature review. J Clin Neurol. (2023) 19:96–8. doi: 10.3988/jcn.2023.19.1.96
20.
ClémentMNéelAToulgoatFWeberMGodmerPHutinPet al. Inflammatory optic neuropathy in granulomatosis with polyangiitis can mimick isolated idiopathic optic neuritis. Eur J Ophthalmol. (2021) 31:245–51. doi: 10.1177/1120672119889008
21.
BennettJLCostelloFChenJJPetzoldABiousseVNewmanNJet al. Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment. Lancet Neurol. (2023) 22:89–100. doi: 10.1016/S1474-4422(22)00187-9
22.
BaskaranABGrebenciucovaEShoemakerTGrahamEL. Current updates on the diagnosis and management of multiple sclerosis for the general neurologist. J Clin Neurol. (2023) 19:217–29. doi: 10.3988/jcn.2022.0208
23.
BalcerLJ. Optic neuritis. N Engl J Med. (2006) 354:1273–80. doi: 10.1056/NEJMcp053247
24.
ToosyATMasonDFMillerDH. Optic neuritis. Lancet Neurol. (2014) 13:83–99. doi: 10.1016/S1474-4422(13)70259-X
25.
KupersmithMJBurdeRMWarrenFAKlingeleTGFrohmanLPMitnickH. Autoimmune optic neuropathy: evaluation and treatment. J Neurol Neurosurg Psychiatry. (1988) 51:1381–6. doi: 10.1136/jnnp.51.11.1381
26.
PetzoldAPlantGT. Diagnosis and classification of autoimmune optic neuropathy. Autoimmun Rev. (2014) 13:539–45. doi: 10.1016/j.autrev.2014.01.009
27.
BeldenCJHamedLMMancusoAA. Bilateral isolated retrobulbar optic neuropathy in limited Wegener’s granulomatosis. J Neuroophthalmol. (1993) 13:119–23.
28.
BlaisePRobe-CollignonNAndrisCRakicJ-M. Wegener’s granulomatosis and posterior ischemic optic neuropathy: atypical associated conditions. Eur J Intern Med. (2007) 18:326–7. doi: 10.1016/j.ejim.2006.11.013
29.
HuchzermeyerCMardinCHolbachLZwerinaJSchettGRechJ. Successful remission induction with a combination therapy of rituximab, cyclophosphamide, and steroids in a patient with refractory optic neuritis in Wegener’s granulomatosis. Clin Rheumatol. (2013) 32:97–101. doi: 10.1007/s10067-010-1561-9
30.
NagaokaTIkedaKHirayamaTYamamotoTIwasakiY. Wegener granulomatosis-associated optic perineural hypertrophy and optic neuropathy. Intern Med. (2012) 51:227–8. doi: 10.2169/internalmedicine.51.6532
31.
TakazawaTIkedaKNagaokaTHirayamaTYamamotoTYanagihashiMet al. Wegener granulomatosis-associated optic perineuritis. Orbit. (2014) 33:13–6. doi: 10.3109/01676830.2013.841716
32.
NakajimaHYamaneKKimuraFOkuH. Optic perineuritis associated with antineutrophil cytoplasmic autoantibody-related hypertrophic pachymeningitis: a case report. Neurol Sci. (2016) 37:641–3. doi: 10.1007/s10072-015-2454-0
33.
SugaKNomotoYSudoAIsogaiJSuzukiYKagamiS-I. Granulomatosis with polyangiitis complicated with refractory optic neuritis and maxillary osteomyelitis. Mod Rheumatol Case Rep. (2020) 4:79–83. doi: 10.1080/24725625.2019.1638050
34.
MitsuhashiMYoshimiRKishimotoDHidekawaCIizukaYSakuraiNet al. Refractory optic perineuritis related to granulomatosis with polyangiitis treated with intensive immunosuppressive therapy combined with plasma exchange. Mod Rheumatol Case Rep. (2020) 4:84–9. doi: 10.1080/24725625.2019.1649857
35.
Sato-AkushichiMKinouchiRKawaiNNomuraK. Optic neuropathy secondary to granulomatosis with polyangiitis in a patient with Graves’ disease: a case report. J Med Case Rep. (2021) 15:618–6. doi: 10.1186/s13256-021-03207-4
Summary
Keywords
optic neuritis, granulomatosis with polyangiitis, Wegener’s granulomatosis, vasculitis, ischemic optic neuropathy
Citation
Kim Y, Woo T, Lee S-U, Park E, Shin H-J, Sim J, Kim GJ and Kim J-S (2025) Optic neuropathy as an early manifestation of granulomatosis with polyangiitis: a case report and literature review. Front. Med. 12:1515622. doi: 10.3389/fmed.2025.1515622
Received
23 October 2024
Accepted
31 January 2025
Published
18 February 2025
Volume
12 - 2025
Edited by
Sachin Kedar, Emory University, United States
Reviewed by
Essam Mohamed Elmatbouly Saber, Benha University, Egypt
Valerie Purvin, Midwest Eye Institute, United States
Updates
Copyright
© 2025 Kim, Woo, Lee, Park, Shin, Sim, Kim and Kim.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Sun-Uk Lee, sulee716@gmail.com
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.